Robin Steigerwald

Introduction

Robin Steigerwald, located in Munich, Germany, is an accomplished inventor with a notable portfolio of 26 patents. His pioneering work in the field of immunology has significant implications for vaccine development, particularly in combating filovirus infections.

Latest Patents

Among his latest inventions is a groundbreaking patent titled "Methods and compositions for inducing protective immunity against filovirus infection." This innovation focuses on creating compositions, vaccines, and methods specifically designed to induce protective immunity against multiple subtypes of Ebola and Marburg viruses. Another significant patent is for the "Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine," which details the use of recombinant MVA comprising a nucleotide sequence encoding for a structural protein of the equine encephalitis virus. This invention highlights its potential in treating and preventing diseases caused by various strains of equine encephalitis viruses.

Career Highlights

Robin Steigerwald has made a profound impact in the biotechnology sector, particularly while working with notable companies such as Bavarian Nordic A/S and Janssen Vaccines & Prevention B.V. His expertise in vaccine technology and viral immunology has paved the way for innovative solutions in public health.

Collaborations

Throughout his career, Steigerwald has collaborated with distinguished professionals in the industry, including his coworkers Ulrike Dirmeier and Ariane Volkmann. These collaborations exemplify the collective effort in advancing scientific research and technology in vaccine development.

Conclusion

In summary, Robin Steigerwald stands out as a leading innovator in the realm of vaccine development, contributing to the ongoing fight against viral infections. His extensive patent portfolio and collaborative efforts reflect his commitment to advancing medical science and public health initiatives.